natgillin/translations-raw huggingface dataset:
The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John’s Wort (Hypericum perforatum)) may also lead to reduced rivaroxaban plasma concentrations.
Istodobna primjena rivaroksabana s drugim jakim induktorima CYP3A4 (npr. fenitoinom, karbamazepinom, fenobarbitalom ili gospinom travom (Hypericum perforatum)) također može dovesti do smanjene koncentracije rivaroksabana u plazmi.
The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John’s Wort (Hypericum perforatum)) may also lead to reduced rivaroxaban plasma concentrations.
Istodobna primjena rivaroksabana s drugim jakim induktorima CYP3A4 (npr. fenitoinom, karbamazepinom, fenobarbitalom ili gospinom travom(Hypericum perforatum)) također može dovesti do smanjene koncentracije rivaroksabana u plazmi.
The concomitant use of Simponi with these biologics is not recommended because of the possibility of an increased risk of infection, and other potential pharmacological interactions.
Istodobna primjena lijeka Simponi s tim biološkim lijekovima se ne preporučuje zbog mogućeg povećanog rizika od infekcije i drugih mogućih farmakoloških interakcija.
The concomitant use of sirolimus with a calcineurin inhibitor may increase the risk of calcineurin inhibitor-induced HUS/TTP/TMA.
Istodobna primjena sirolimusa s inhibitorima kalcineurina može povećati rizik od hemolitičko- uremijskog sindroma, trombotične trombocitopenične purpure i trombotske mikroangiopatije koji su izazvani inhibitorima kalcineurina.
The concomitant use of Telmisartan Actavis with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Telmisartan Actavis s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Telmisartan Teva Pharma with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva Pharma s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove o 4.5 i 5.1.).
The concomitant use of Telmisartan Teva Pharma with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva Pharma s lijekovima koji sadrže aliskiren kontrainidicrana je u bolesnika sa šećernom bolesti ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1.).
The concomitant use of Telmisartan Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva s lijekovima koji sadrže aliskiren kontrainidicrana je u bolesnika sa šećernom bolesti ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove o 4.5 i 5.1.).
The concomitant use of Telmisartan Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva s lijekovima koji sadrže aliskiren kontrainidicrana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Telmisartan Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva s lijekovima koji sadrže aliskiren kontrainidicrana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1.).
The concomitant use of telmisartan with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.2, 4.4, 4.5).
Istodobna primjena telmisartana s aliskirenom je kontraindicirana kod bolesnika s dijabetes melitusom ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove o 4.2, 4.4, 4.5).
The concomitant use of telmisartan/amlodipine with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena kombinacije telmisartan/amlodipin s lijekovima koji sadrže aliskiren kontrainidicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of telmisartan/amlodipine with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena kombinacije telmisartan/amlodipin s lijekovima koji sadrže aliskiren kontrainidicrana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of telmisartan/amlodipine with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5, and 5.1).
Istodobna primjena kombinacije telmisartan/amlodipin s lijekovima koji sadrže aliskiren kontrainidicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of ticagrelor increases the exposure to dabigatran and may show pharmacodynamic interaction, which may result in an increased risk of bleeding (see section 4.5).
Istovremena primjena tikagrelora povećava izloženost dabigatranu te može doći do farmakodinamičke interakcije koja može rezultirati povećanim rizikom od krvarenja (vidjeti dio 4.5).
The concomitant use of Tolucombi with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Tolucombi s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of vandetanib with strong CYP3A4 inducers (such as rifampicin, St John’s Wort, carbamazepine, phenobarbital) should be avoided (see section 4.5).
Treba izbjegavati istodobnu primjenu vandetaniba i snažnih induktora CYP3A4 (kao što su rifampicin, gospina trava, karbamazepin, fenobarbital) (vidjeti dio 4.5).
The concomitant use of Xadago and fluoxetine or fluvoxamine should be avoided (see section 4.4), this precaution is based on the occurrence of serious adverse reactions (e.g. serotonin syndrome), although rare, that have occurred when SSRIs and dextromethorphan have been used with MAO inhibitors.
Potrebno je izbjegavati istovremenu upotrebu lijeka Xadago i fluoksetina ili fluvoksamina (vidjeti dio 4.4), ova se mjera opreza temelji na pojavi ozbiljnih nuspojava (npr. serotoninski sindrom), iako rijetko, koji se javlja kada se SSRI-i i dekstrometorfan primjenjuju s MAO inhibitorima.
The concomitant use of YENTREVE with selective, reversible MAOIs, like moclobemide, is not recommended (see section 4.4).
Ne preporučuje se istodobna primjena lijeka YENTREVE sa selektivnim reverzibilnim inhibitorima MAO, poput moklobemida (vidjeti dio 4.4).
The concurrent administration of a single dose of oral clarithromycin, (a strong CYP3A4 inhibitor probe) with a single dose of oral Eurartesim led to a modest increase (≤2-fold) in piperaquine exposure in healthy adult subjects.
Istovremena primjena jedne peroralne doze klaritromicina (jakog probnog inhibitora CYP3A4) i jedne peroralne doze Eurartesima dovela je u zdravih odraslih ispitanika do malog povećanja (≤ 2 puta) izloženosti piperakinu.
The concurrent administration of Kineret and etanercept or other TNF antagonists is not recommended (see section 4.5).
Istodobna primjena Kinereta i etanercepta ili drugih antagonista TNF-a se ne preporučuje (vidjeti dio 4.5).
The concurrent administration of live vaccines with Flixabi is not recommended.
Ne preporučuje se istodobna primjena živih cjepiva s lijekom Flixabi.
The concurrent administration of oral Eurartesim with 7.5 mg oral midazolam, a CYP3A4 probe substrate, led to a modest increase (≤2-fold) in midazolam and its metabolites exposures in healthy adult subjects.
Istovremena primjena oralnog Eurartesima sa 7,5 mg oralnog midazolama, probnog supstrata CYP3A4, dovela je u zdravih odraslih ispitanika do malog povećanja izloženosti (≤ 2 puta) midazolamu i njegovim metabolitima.
The concurrent administration of thiopental, however, may slightly increase sensitivity to adrenaline induced cardiac arrhythmias.
Istodobna primjena tiopentala, međutim, može blago povećati osjetljivost na srčane aritmije izazvane adrenalinom.
The concurrent administration of thiopental, however, may slightly increase sensitivity to adrenaline- induced cardiac arrhythmias.
Istodobna primjena tiopentala, međutim, može blago povećati osjetljivost na srčane aritmije izazvane adrenalinom.
The concurrent adminstration of live vaccines with Inflectra is not recommended.
Ne preporučuje se istodobna primjena živih cjepiva s lijekom Inflectra.
The concurrent use of Fluenz Tetra with antiviral agents that are active against influenza A and/or B viruses has not been evaluated.
Istodobna primjena cjepiva Fluenz Tetra i antivirusnih lijekova koji djeluju protiv virusa influence A i/ili B nije bila ispitivana.
The concurrent use of FLUENZ with antiviral agents that are active against influenza A and/or B viruses has not been evaluated.
Istodobna primjena cjepiva FLUENZ i antivirusnih lijekova koji djeluju protiv virusa influence A i/ili B nije bila ispitivana.
The concurrent use of haematopoietic growth factors and Jakavi has not been studied.
Istodobna primjena hematopoetskih čimbenika rasta i Jakavija nije do sada proučavana.
The concurrent use of Kineret with etanercept or any other TNF antagonist is not recommended (see section 4.4).
Istodobna primjena Kinereta s etanerceptom ili bilo kojim drugim antagonistom TNF-a se ne preporučuje (vidjeti dio 4.4).
The concurrent use of prolonged-release exenatide and immediate-release exenatide has not been studied and is not recommended.
Istodobna primjena eksenatida s produljenim oslobađanjem i eksenatida s trenutnim oslobađanjem nije ispitivana te se ne preporučuje.
The concurrent use of prolonged-release exenatide with insulin, D-phenylalanine derivatives (meglitinides), alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors or other GLP-1 receptor agonists has not been studied.
Nije ispitivana istodobna primjena eksenatida s produljenim oslobađanjem s inzulinom, derivatima D-fenilalanina (meglitinidima), inhibitorima alfa-glukozidaze, inhibitorima dipeptidil peptidaze-4 ili drugim agonistima GLP-1 receptora.
The concurrent use of strong CYP3A inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifampicin, and St. John’s wort, should be avoided (see section 4.4).
Treba izbjegavati istodobnu primjenu snažnih induktora CYP3A, uključujući, no ne ograničavajući se na karbamazepin, fenobarbital, fenitoin, rifampicin i gospinu travu (vidjeti dio 4.4).
The condition is known as ‘inborn errors in primary bile acid synthesis’.
Stanje je poznato kao „prirođene greške u sintezi primarne žučne kiseline”.
The conditions of the Pregnancy Prevention Programme for lenalidomide must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.
Uvjeti Programa prevencije trudnoće za lenalidomid moraju se ispuniti za sve bolesnice, osim za one za koje postoje pouzdani dokazi da nemaju reproduktivnog potencijala.
The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.
Svi bolesnici moraju ispuniti uvjete Programa prevencije trudnoće, osim ako postoji pouzdan dokaz da bolesnik nije u reproduktivnoj dobi.
The conditions of the Thalidomide Celgene Pregnancy Prevention Programme must be fulfilled for all male and female patients.
Uvjete Programa prevencije trudnoće za Thalidomide Celgene moraju ispuniti svi bolesnici i bolesnice.
The conduct and results of these tests should be recorded on your child's Patient Alert Card.
Provođenje i rezultati ovih pretraga moraju se zabilježiti na Kartici s upozorenjima za bolesnika Vašeg djeteta.
The conduct of these tests should be recorded on your Patient Alert Card.
Rezultate tih testova treba zabilježiti u Vašoj kartici s upozorenjima za bolesnika.
The conduction abnormalities observed both in clinical trials and post- marketing were typically transient, asymptomatic and resolved within the first 24 hours after treatment initiation.
Poremećaji u provođenju uočeni kako u kliničkim ispitivanjima tako i nakon stavljanja lijeka u promet obično su bili prolazni, asimptomatski i povukli su se unutar prva 24 sata od početka liječenja.
The confirmed OIRR and other efficacy results per investigator assessment are presented in Table 10.
Potvrđeni OIRR i ostali rezultati djelotvornosti prema procjeni ispitivača prikazani su u tablici 10.
The congenital factor XIII A-subunit deficiency should be confirmed by appropriate diagnostic procedures including factor XIII activity and immunoassay and if applicable genotyping.
Prirođeni nedostatak faktora XIII A-podjedinice potrebno je potvrditi odgovarajućim dijagnostičkim postupcima uključujući određivanje aktivnosti faktora XIII, imunoesejom i, ako je primjenjivo, genotipizacijom.
The connected perfusion tubing equipment of the precision pump is prefilled with the diluted Removab solution for infusion.
Oprema perfuzijskih cijevi spojena s preciznom pumpom prethodno se napuni razrijeđenom Removab otopinom za infuziju.
The consequence of this for the clinical use of the drug is unknown.
Posljedice ovoga, na kliničku upotrebu lijeka nisu poznate.
The consequent increase in dopaminergic stimulation can lead to the dopaminergic side effects observed after treatment with COMT inhibitors.
Posljedično povećanje dopaminergičke stimulacije može voditi do dopaminergičkih nuspojava opaženih nakon liječenja COMT inhibitorima.
The consolidated analysis of Paediatric AIDS Clinical Trials Group (PACTG) protocols 245, 356, 366, 377, and 403 allowed for the evaluation of paediatric patients less than 3 months of age (n=17) enrolled in these PACTG studies.
Skupna analiza studija iz programa pedijatrijskih kliničkih isptivanja AIDS-a (PACTG) protokoli 245, 356, 366, 377, i 403 omogućila je i procjenu pedijatrijskih bolesnika u dobi mlađoj od 3 mjeseca (n=17).
The container and the solution should be inspected prior to use as described in section 6.6.
Spremnik i otopinu treba prekontrolirati prije uporabe, kao što je to opisano u dijelu 6.6.
The container and the solution should be inspected prior to use.
Spremnik i otopinu treba prekontrolirati prije uporabe.
The container can be broached once more only during the next 28 days, then discarded immediately after use.
Spremnik se može probušiti samo jedanput tijekom sljedećih 28 dana, a zatim se mora baciti neposredno nakon primjene.
The container closure system is comprised of a dual-chamber cartridge, a center stopper, a crimp cap (containing a rubber seal) sealing the first chamber containing lyophilised powder and an end stopper sealing the second chamber containing the solvent for mixing.
Zatvoreni sustav spremnika sastoji se od uloška sa dvije komore, središnjeg čepa, navojnog zatvarača (sadrži gumeni čep) koji brtvi prvu komoru s liofiliziranim praškom i zadnjeg čepa koji brtvi drugu komoru s otapalom za miješanje.
The container of this vaccine contains latex rubber.
Spremnik ovog cjepiva sadrži lateks-gumu.
The content and format of the MULTAQ Information Card and the Prescriber check list, together with the communication and distribution plan should be agreed with the National Competent Authority in each Member State prior to distribution.
Sadržaj i format kartice s informacijama o lijeku MULTAQ te kontrolnog popisa za liječnika propisivača, zajedno s planom komunikacije i distribucije, treba dogovoriti s nadležnim tijelom pojedine države članice prije distribucije.
The content must be clear and colourless after reconstitution.
Nakon pripreme sadržaj mora biti bistar i bezbojan.
The content must be clear and colourless.
Sadržaj mora biti bistar i bezbojan.
The content of a full pipette is applied onto the animal’s skin, after parting the fur.
Sadržaj napunjene pipete primjenjuje se na kožu životinje nakon razmicanja krzna.
The content of each vial must be reconstituted by slowly adding 25 ml of water for injections.
Sadržaj svake bočice mora se rekonstituirati polaganim dodavanjem 25 ml vode za injekcije.
The content of one full applicator (appropriate to the cat’s weight) is applied directly to the cat’s skin after parting the hair, in one spot on the middle of the neck.
Sadržaj jednog punog aplikatora (primjeren težini mačke) primjenjuje se u jednu točku na sredini vrata izravno na kožu mačke nakon što se dlaka razmakne.
The content of one full Bravecto pipette is applied to the dog or cat’s skin between the shoulder blades of the dog and at the base of the skull of the cat.
Sadržaj jedne u potpunosti napunjene pipete VMP-om Bravecto primjenjuje se na kožu psa ili mačke, između lopatica psa te na bazu lubanje mačke.
The content of one full Certifect pipette (appropriate to the dog’s weight) is applied directly to the dog’s skin, after parting its fur, in two separate spots (halfway down the back of the neck, and at the base of the neck).
Sadržaj jedne pune Certifect pipete (primjeren težini psa) primjenjuje se izravno na kožu psa nakon što se razmakne krzno, i to na dvije različite točke (u sredini vrata između zatiljka i lopatica, te ispred lopatica).
The content of one full Vectra 3D applicator is applied directly to the dog’s skin, after parting its fur, either in one or more spots on the back, depending on the dog’s weight, or in a continuous line along the centre of the back from the base of the tail to the shoulder blades.
Nakon što se razmakne krzno psa, sadržaj jednog punog Vectra 3D aplikatora primjenjuje se izravno na kožu psa u jednoj ili više točaka na leđima, ovisno o tjelesnoj težini psa ili u kontinuiranoj liniji uzduž centra leđa od baze repa do lopatica.
The content of one full Vectra Felis applicator is applied directly to the cat’s skin, after parting its fur, at the base of the cat’s head.
Sadržaj jednog punog Vectra Felis aplikatora primjenjuje se izravno na kožu mačke, nakon što se krzno razmakne u bazi glave mačke.
The content of one tube covers a treatment area of 25 cm2 (e.g.
Sadržaj jedne tube pokriva liječeno područje od 25 cm2 (npr.
The content of sodium and potassium per infusion should be taken into account if administered in patients with cardiovascular diseases and/or renal impairment.
Sadržaj natrija i kalija po infuziji potrebno je kontrolirati u bolesnika s kardiovaskularnim bolestima i/ili oštećenjem funkcije bubrega.
The content of sodium is greater than 1 mmol (up to 37 mg per dose).
Lijek sadrži više od 1 mmola natrija (do 37 mg po dozi).
The content of the ampoule is to be used as follows:
Sadržaj bočice mora se iskoristiti na sljedeći način:
The content of the ampoule(s) is thawed rapidly by immersing in clean water at 25–27 °C. Gently swirl the ampoule(s) to disperse the contents.
Sadržaj ampule(a) treba naglo odmrznuti uranjanjem u čistu vodu na 25–27 °C. Polako protresti ampulom da bi se sadržaj izmiješao.
The content of the prefilled syringe should be visually inspected for any foreign particulate matter and/or change in physical appearance prior to administration.
Sadržaj napunjene štrcaljke treba prije primjene vizualno provjeriti na prisutnost bilo kakvih stranih čestica i/ili promjenu fizičkog izgleda.
The content of the syringe should be inspected visually both before and after shaking for any foreign particulate matter and/or abnormal physical appearance prior to administration.
Sadržaj štrcaljke treba i prije i nakon protresanja vizualno ispitati na eventualno prisustvo stranih čestica i/ili promjenu fizičkog izgleda cjepiva prije primjene.
The content of the tube should be applied to one treatment area of 25 cm2.
Sadržaj tube treba nanijeti na jedno liječeno područje od 25 cm2.
The content of the vial should be inspected visually both before and after shaking for any foreign particulate matter and/or abnormal physical appearance prior to administration.
Sadržaj bočice treba i prije i nakon protresanja vizualno ispitati na eventualno prisustvo stranih čestica i/ili promjenu fizičkog izgleda cjepiva prije primjene.
The content of the vials should be inspected for particulate matter and discolouration (the concentrate for solution for infusion should be clear to slightly opalescent and colourless to slightly yellow without visible particles) prior to administration.
Prije primjene potrebno je pregledati sadržaj bočica kako bi se utvrdilo sadrži li čestice i je li promijenio boju (koncentrat za otopinu za infuziju mora biti bistar do blago opalescentan te bezbojan do bljedožut, bez vidljivih čestica).
The contents are poured into a drinking glass, the jar filled a second and third time with water and the contents transferred into the drinking glass, so that approximately 30 ml of test solution is obtained.
Sadržaj spremnika preliti u čašu te napuniti spremnik vodom i ponoviti postupak još dva puta, tako da se dobije oko 30 ml otopine za testiranje.
The contents of a cup (1,000 doses only) can be added to Solvent Oculo/Nasal using the included adapter and administered after connecting the included dropper.
Sadržaj čašice (samo 1000 doza) može se dodati okulo/nazalnom otapalu pomoću adaptera uključenog u pakovanje i primijeniti nakon spajanja kapaljke uključene u pakovanje.
The contents of a single vial of Versican Plus DHPPi or Versican Plus Pi should be reconstituted with the contents of a single vial of Versican Plus L4 (instead of the solvent).
Sadržaj jedne bočice Versican Plus DHPPi ili Versican Plus Pi treba rekonstituirati sa sadržajem jedne bočice Versican Plus L4 (umjesto otapala).
The contents of a single vial of Versican Plus DHPPi or Versican Plus Pi should be reconstituted with the contents of a single vial of Versican Plus L4 (instead of the solvent).
Sadržaj jedne bočice Versican Plus DHPPi ili Versican Plus Pi treba se rekonstituirati sa sadržajem jedne bočice Versican Plus L4 (umjesto otapala).
The contents of a single vial of Versican Plus DHPPi should be reconstituted with the contents of a single vial of Versican Plus L4 (instead of the solvent).
Sadržaj jedne bočice Versican DHPPi treba rekonstituirati sa sadržajem jedne bočice Versican Plus L4 umjesto s otapalom.
The contents of a single vial of Versican Plus DHPPi should be reconstituted with the contents of a single vial of Versican Plus L4 (instead of the solvent).
Sadržaj jedne bočice Versican Plus DHPPi rekonstituirati sa sadržajem jedne bočice Versican Plus L4 umjesto sa otapalom.
The contents of a single vial of Versican Plus DHPPi should be reconstituted with the contents of a single vial of Versiguard Rabies (instead of the solvent).
Sadržaj jedne bočice Versican Plus DHPPi treba rekonstituirati sa sadržajem jedne bočice Versiguard Rabies umjesto s otapalom.
The contents of a single vial of Versican Plus Pi should be reconstituted with the contents of a single vial of Versican Plus L4 (instead of the solvent).
Sadržaj jedne bočice Versican Plus Pi treba rekonstituirati sa sadržajem jedne bočice Versican Plus L4 umjesto s otapalom.
The contents of a vial should be used immediately after piercing of the rubber stopper.
Sadržaj bočice mora se upotrijebiti odmah nakon probijanja gumenog čepa.
The contents of a vial should be used immediately after piercing the rubber stopper.
Sadržaj bočice mora se upotrijebiti odmah nakon što se probije gumeni čep.